





¹ Integrated Program in Neuroscience, McGill University, Montreal. ² Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal, Montreal (CRIR). ³ Department of Anesthesiology and Pain Medicine, Medicine, Université de Montréal. ⁴ Centre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Coeur de Montréal, CIUSSS du Nord-de-l'Île-de-Montréal, Montreal. ⁵ School of Physical and Occupational Therapy, McGill University, Montreal. ⁶ Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre. ⁷ Department of Physiology and Pharmacology and Department of Psychology, Western University. ⁸ Jewish Rehabilitation Hospital, CISSS-Laval, Laval.

INTRODUCTION

• 10 to 20% of people infected with SARS-CoV-2 develop symptoms that extend beyond 12 weeks post-infection, which is defined as post COVID-19 condition (PC19)¹.

 Six months post-infection, the three most common symptoms are fatigue, brain fog, and post-exertional malaise (PEM)².

• The brain is among the organs affected by COVID-19, where grey matter loss³ and decreased motor cortex excitability⁴ have been reported.

• The neural correlates associated with PC19 symptoms are still not properly understood.

Using electroencephalography (EEG), we will study PC19 brain features in terms of:

Desynchronization **1.** Motor-Related Beta (MRBDs), as they have been linked to fatigue and aging (**Fig. 1**)⁵.

2. Functional Connectivity (FC) and Graph (GTA) Analysis Theory study neural to communication and states of consciousness⁶.



AIMS & HYPOTHESES

• The objective is to quantify abnormal brain oscillatory patterns present in PC19 individuals and their association with the three main lingering symptoms, namely fatigue, PEM and brain fog.

• We expect to find features typical of aging, such as larger MRBD⁵ amplitude, that will be positively correlated to fatigue. We also expect increased symptoms to be associated with alterations in FC and GTA features.

Identifying Electroencephalography Biomarkers of Post COVID-19 Condition Symptoms

Monserrat Casado Sánchez^{1,2}, Catherine Duclos^{3,4}, Tania Janaudis-Ferreira^{5,6}, Adrian M. Owen⁷ & Marie-Hélène Boudrias^{2,5,8}

STUDY DESIGN & METHODS



Data collected from 16 PC19 individuals and 3 matched controls. Scores from the PC19 group in the Creyos tasks

	PC19 n=16	Control n=3	Creyos		
Teet			Cognitive dommain	Task	Sco
Test	wean (SD)	iviean (SD)	Concentration	Double trouble	68%
Age	43.5 (9.9)	39 (4.3)	Concentration	Feature Match	81%
Hospitalizations	0	N/A	Short Term Memory	Monkey Ladder	72%
Time since infection	26 months	Ν/Δ	Short Term Memory	Paired Associates	71%
	20 111011113		Reasoning	Rotations	66%
FSS	56.5 (5.8)	29.6 (24.6)	Reasoning	Odd one out	68%
CFQ	61.6 (16.0)	18.6 (8.6)	Verbal	Grammatical Reasoning	; 76%
DSQ-PEM	100%*	0%*	Verbal	Digit span	60%
					-

Figure 3. Mean scores are represented with the standard deviation (SD). FSS > 36 may indicate severe fatigue. $CFQ \ge 43$ is defined as a high score. DSQ-PEM percentages represent the participants who met the criteria for PEM.

PRELIMINARY RESULTS

Figure 4. Average scores of the PC19 group are represented in percentiles. The normal distribution is a score of 100%. (n) represent the number of participants whose scores were valid and taken into account for the averages





DISCUSSION

vre (n)

- % (14)
- % (15)
- % (15)
- 6 (14
- % **(1**4)
- % **(**15)
- % (15) % (14)

Preliminary results show that individuals from the PC19 group have scores indicating severe fatigue (FSS), high cognitive failures (CFQ) and present symptoms of PEM (DSQ-PEM)

• The percentiles observed in the Creyos tasks show that some domains, such as reasoning and verbal habilities are more impaired than other in this population.

 EEG patterns will be extracted and analyzed in relation to the observed clinical outcomes.

SIGNIFICANCE

 There are currently no straightforward ways to diagnose, prevent or treat PC19.

• An estimated 1% of individuals in Canada are still unable to return to their pre-COVID-19 level of functioning due to the debilitating symptoms of this condition⁷.

• This study represents a critical step for identifying biomarkers of PC19, which could ultimately contribute to developing effective techniques diagnostic targeted and debilitating treatments to improve the symptoms experienced by this population.

ACKNOWLEDGEMENTS

This study is funded by a grant from the Quebec Bio-Imaging Network (QBIN). A scholarship from the National Council from Science and Technology (CONACyT - Mexico) was awarded to Monserrat Casado to fund her graduate studies.

REFERENCES

[1]World Health Organization, 2023 [2] Davis et al. ÉClinicalMedicine 2021 [3] Douaud *et al.* Nature 2022 [4] Ortelli et al. Euro J Neurol 2022 [5] Xifra-Porxas et al. Neurolmage 2019 [6] Bullmore et al. Nat Rev Neurosci 2009 [7] Government of Canada, 2022.